Dasabuvir

Overview of the medication Dasabuvir

Dasabuvir
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Dasabuvir is an antiviral drug used in the treatment of hepatitis C. It is a non-nucleoside inhibitor of the hepatitis C virus (HCV) RNA polymerase, specifically targeting the NS5B protein. Dasabuvir is commonly used in combination with other antiviral agents to enhance its efficacy in clearing the virus from the body.

Mechanism of Action

Dasabuvir works by inhibiting the NS5B RNA-dependent RNA polymerase, an enzyme crucial for the replication of the hepatitis C virus. By binding to the polymerase, dasabuvir prevents the virus from replicating its RNA, thereby reducing the viral load in the patient's body.

Clinical Use

Dasabuvir is primarily used in combination with other antiviral medications, such as ombitasvir, paritaprevir, and ritonavir, in a regimen known as the "3D regimen" or "Viekira Pak." This combination therapy is effective against genotype 1 of the hepatitis C virus, which is the most common genotype in many parts of the world.

Administration

Dasabuvir is administered orally, typically in the form of tablets. The dosage and duration of treatment depend on the specific combination regimen and the patient's genotype and liver function status.

Side Effects

Common side effects of dasabuvir include fatigue, nausea, itching, and insomnia. More serious side effects can occur, especially when used in combination with other drugs, and may include liver dysfunction and allergic reactions.

Pharmacokinetics

Dasabuvir is metabolized in the liver and excreted primarily in the feces. Its pharmacokinetic profile is influenced by factors such as liver function and the presence of other medications.

Related pages

• Hepatitis C
• Antiviral drug
• RNA polymerase
• NS5B protein

• 
  Dasabuvir

• 
  Dasabuvir